Inno4Vac Subtopic 1 Meeting Held in Braunschweig
- 5 hours ago
- 1 min read
April 2026
Inno4Vac ST 1 members convened on 08-09 April 2026 in Braunschweig, Germany, for a face-to-face meeting hosted by project partner Helmholtz-Zentrum für Infektionsforschung GmbH (HZI)
Led by the University of Oslo and GSK, Subtopic 1 focuses on the development of a systems immunology platform. This subtopic addresses the application of artificial intelligence, big data analysis, and computational modelling to support the creation of an open‑access, cloud‑based platform aimed at predicting vaccine effectiveness and the likelihood of success in later stages of vaccine development
The meeting featured scientific updates on BCR experiments and sequencing data analysis, advances in in silico affinity maturation and immune prediction, as well as discussions on the integration and long‑term sustainability of the VAXPRED online platform. It also provided an opportunity to discuss sustainability strategies and future plans for maintaining and expanding its impact beyond the project duration.
As the project heads into its last remaining months, partners are looking forward to finalizing project outputs for incorporation into existing pipelines and processes.
-------------------------
Contact:
Dr. Nicola Viebig (Director of Research at the European Vaccine Initiative)
Email: nicola.viebig@euvaccine.eu
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101007799 (Inno4Vac). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA (www.imi.europa.eu). This communication reflects the author´s view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.
Comments